Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2010.4.2-3 | Award Amount: 3.75M | Year: 2010
The emergence of suicidality in patients receiving drug treatment is of concern because of the overall burden and the possible link with completed suicide. The lack of uniform requirements for defining, detecting and recording suicidality and the presence of disease related confounders create major problems. It is possible that Medication-Related Suicidality (MRS) differs from Psychopathology-Related Suicidality (PRS) in terms of phenomenology, clinical expression and time course, and may vary between children and adults. Unlike PRS, the time-course of MRS may be associated with possible differences in drug pharmacokinetics; abrupt onset; absence of suicidality prior to start of medication; and emergence of suicidality related co-morbidities after treatment. This proposal will focus on developing a web-based comprehensive methodology for the assessment and monitoring of suicidality and its mediators in children and adolescents using the HealthTrackerTM (a paediatric web-based health outcome monitoring system), with the aim of developing a Suicidality Assessment and Monitoring Module, a Bio-psycho-social Mediators of Suicidality Assessment Module, and a Suicidality-Related Psychiatric and Physical Illness Module. The information obtained will be used to computer-generate classification of suicidality using the Classification of Suicide-Related Thoughts and Behaviour (Silverman et al, 2007) and the Columbia Classification Algorithm of Suicidal Assessment (C-CASA) (Posner et al, 2007). The existing Medication Characteristics Module will be expanded to allow documentation of pharmacological characteristics of medication, to explore whether they mediate MRS. The methodology will then be tested in 3 paediatric observational trials (risperidone in conduct disorder; fluoxetine in depression, and montelukast in bronchial asthma) and standardized, which can be used pharmacovigilance and in epidemiological, observational, and registration trials.
Agency: European Commission | Branch: FP7 | Program: CSA-CA | Phase: HEALTH.2011.3.3-4 | Award Amount: 2.27M | Year: 2011
On the regional level, Europe has one of the highest levels of resources for mental health care. Despite this, the high burden and impact of mental disorders in Europe is expected to rise. ROAdmap for Mental health Research (ROAMER) is designed to develop a comprehensive, consensus-based roadmap to promote and integrate mental health and well-being research in Europe. Research advances and innovations are to be devoted to decreasing the burden of mental disorders and increasing the mental health and well-being of Europeans. ROAMER will combine a neutral, fact-based methodology with extensive stakeholder involvement in consultation and dissemination. During the kick-off phase, the methodology (including comprehensive EU-wide indicators to assess the current state of the art, gaps and advances) and the desired situation (scoping and objectives) will be finalised. Secondly, the current state of the art will be examined, using these tools. In the third phase, the desired situation will be compared with the current situation to identify gaps and advances. Phase four prioritises these gaps and advances, as well as solutions. In the fifth phase, this information is translated into roadmaps covering infrastructures, capacity building and funding strategies for scientific areas relevant to mental health and well-being: biomedical, psychological, social, economic and public health. Geographical, interdisciplinary, developmental, gender and age perspectives will be taken into account. To achieve consensus among a broad group of scientists, service users, carers, government and funding institutions and other stakeholders, ROAMER uses web-based surveys, scientific workshops, scientific advisory board meetings, stakeholder meetings, consensus meetings, and policy meetings. The consortium consists of leading experts in the field, and is well balanced in terms of geographical distribution and complementary expertises across all relevant aspects of mental health research.
Agency: European Commission | Branch: H2020 | Program: IA | Phase: PHC-20-2014 | Award Amount: 3.63M | Year: 2015
The ehcoBUTLER Idea: Nowadays, it is a fact that Europe is ageing. A common characteristic of elders is the frequent occurrence of either physical or mild cognitive impairments. This situation brings new challenges in how to improve the independence and quality of life of elderly people and promote their good health in different ways. The ehcoBUTLER project addresses this challenge by developing an ICT technological platform with both leisure and care apps. The main objective of ehcoBUTLER is to demonstrate the socio-economic benefits from the deployment of several innovative and user led ICT pilot projects based on different business models in order to be able to translate promising results into scalable practice across Europe. How the objectives will be achieved: The ehcoBUTLER Consortium is composed by a multidisciplinary combination of specialist partners on their areas and responsibilities, in order to satisfy the requirements emerging from the EU Call and the particular PHC-20 topic. With this consortium we expect to contribute to break the technological barrier that exists nowadays between the elderly and the ICTs, encouraging the e-Inclusion, to facilitate psychological and cognitive techniques and support procedures, both for the elderly people and for the informal and formal caregivers, to develop an interoperable and open ICT platform particularly designed and adapted to elderly people, to demonstrate the ROI from several four business models based on the deployment of this ICT platform and to generate an ecosystem for apps provider that will allow end users to integrate all the leisure and care related activities in just one platform. To ensure that the platform can be scaled to an operational deployment in the European Market we will deploy ehcoBUTLER in 7 countries and 8 pilot sites to reach the higher number of users and to test the suitability of ehcoBUTLER in different but related business cases.
Agency: European Commission | Branch: H2020 | Program: SGA-RIA | Phase: FETFLAGSHIP | Award Amount: 89.00M | Year: 2016
This project is the second in the series of EC-financed parts of the Graphene Flagship. The Graphene Flagship is a 10 year research and innovation endeavour with a total project cost of 1,000,000,000 euros, funded jointly by the European Commission and member states and associated countries. The first part of the Flagship was a 30-month Collaborative Project, Coordination and Support Action (CP-CSA) under the 7th framework program (2013-2016), while this and the following parts are implemented as Core Projects under the Horizon 2020 framework. The mission of the Graphene Flagship is to take graphene and related layered materials from a state of raw potential to a point where they can revolutionise multiple industries. This will bring a new dimension to future technology a faster, thinner, stronger, flexible, and broadband revolution. Our program will put Europe firmly at the heart of the process, with a manifold return on the EU investment, both in terms of technological innovation and economic growth. To realise this vision, we have brought together a larger European consortium with about 150 partners in 23 countries. The partners represent academia, research institutes and industries, which work closely together in 15 technical work packages and five supporting work packages covering the entire value chain from materials to components and systems. As time progresses, the centre of gravity of the Flagship moves towards applications, which is reflected in the increasing importance of the higher - system - levels of the value chain. In this first core project the main focus is on components and initial system level tasks. The first core project is divided into 4 divisions, which in turn comprise 3 to 5 work packages on related topics. A fifth, external division acts as a link to the parts of the Flagship that are funded by the member states and associated countries, or by other funding sources. This creates a collaborative framework for the entire Flagship.
Agency: European Commission | Branch: FP7 | Program: CP-FP-SICA | Phase: HEALTH.2011.2.4.3-4 | Award Amount: 4.32M | Year: 2012
MEDIGENE project will study genetic and environmental (G x E) determinants of the metabolic syndrome (MetS) in recent immigrants in Europe by a novel approach integrating ancestry of Mediterranean populations in epidemiology, locus refining and Genome Wide Association Studies (GWAS). West Mediterranean shores are place of pre-historical termini of population expansion from Southern Europe and North Africa. Archaeogenetic studies in Europe indicated that Y chromosome and mitochondrial DNA patterns or Ancestry Informative Markers (AIMs) revealed a close relationship between genetic and geographic distances able to locate an individual DNA within few hundred kilometers. The project will use this information in mapping the genetic basis of insulin resistance, cardiovascular and metabolic complications in immigrants (Albanians, Romanians, Turkish, Tunisians, Algerians and Morocco) in host countries France, Spain, Italy and Greece. Ancestry markers and studies on ancient DNA from Roman historical migration in Catalonia will help to give a better picture of the genetic landscape of Europe and North Africa. Genes for MetS will be studied in existing samples from host and home countries by GWAS, locus refining by next-generation sequencing and haplotype mapping. Informative filtered SNPs will be then used in epidemiology and novel DNA samples to reveal G x E interactions and specificities of the pathogenesis of MetS. Genetic findings will be replicated in home countries (Anatolia and North Africa) in the goal to develop markers ethnic specific and significant at a clinical scale. Major impact is expected from dissemination of our findings to prevent the occurrence of MetS and obesity in children and adolescents or in descendants of modern immigration, understanding variability clinical manifestations of MetS in the context of malnutrition and from the novel approach of GWAS strategies by ameliorating the association signal and bursting R&D activities of SMEs.
Agency: European Commission | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2012-ITN | Award Amount: 3.69M | Year: 2013
MARATONE is a Marie Curie Initial Training Network proposal that directly addresses the need for high-level training and career pathways in mental health to increase the inter-sectorial and trans-national employability of young scientists in the academic, public and private sectors to meet the enormous challenge of the 2009 EU Parliament Resolution on Mental Health. The Resolution set out recommendations for a comprehensive and integrated mental health strategy for Europe. MARATONE is designed to address the biggest challenge to implementing this ambitious strategy: the lack of training for career pathways for young scientists in multidisciplinary mental health research. MARATONE is built on the innovative theoretical premise of horizontal epidemiology, the view that psychosocial difficulties associated with mental health disorders are not exclusively determined by the diagnosis of the particular disorder in a vertical, silo-like pattern but horizontally in a manner that reflects commonalities in the lived experience of people with diverse mental health problems. Grounded in this theoretical foundation, MARATONEs multidisciplinary network of partners will collaboratively develop methodologies for measuring the individual and social impact of mental health disorders, so as to create strategies for the social and private sector responses to mental ill health in the form of health promotion and prevention programmes, and at the national level, strategies for human rights protections in policies and programming. The consortium will provide young researchers with scientific expertise in mental health, as well as basic technical and communication skills, including research development and management, international human rights commitments, and commercial exploitation and dissemination.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.2.1-2 | Award Amount: 8.14M | Year: 2014
Neuroimaging (NI) has enormous potential to improve the clinical care of patients with psychiatric disorders, but has yet to deliver. The PSYSCAN project will address this issue directly by developing a NI-based tool that will help clinicians resolve key clinical issues in the management of patients with psychotic disorders. Clinicians will use the tool to assess patients with a standardised set of NI and complementary demographic, clinical, cognitive, and genetic measures. The clinician will enter data on to an iPad, and these data, along with NI data will be electronically transferred to a central facility for analysis. Key features of the analysis include the assessment of NI data at a network level, the integration of NI and non-NI data, and the use of machine learning methods to make predictions specific to the patient being assessed. The results will be delivered to the clinicians iPad and will indicate the likelihood of a given clinical or functional outcome. The tool will have 3 clinical applications. PSYSCAN-Predict will facilitate prediction of the onset of psychosis in high risk subjects. PSYSCAN-Stratify will aid early diagnosis and the stratification of patients with first episode psychosis according to future course and outcome. PSYSCAN-Monitor will allow clinicians to measure progression of the disorder over time. Once developed, the tool will be validated in 2 large scale naturalistic studies using the consortiums extensive network of centres. The validated tool will then be disseminated to clinical centres across the EU. The PSYSCAN project involves a world-class consortium of experts on NI and psychiatry that unites academic centres, SMEs with image processing and computerised testing expertise, a large medical device provider, and the pharmaceutical industry. The consortium is thus ideally suited to translating expertise and knowledge in NI to build a tool that can be used to improve the care of patients with psychiatric disorders
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: NMP-10-2014 | Award Amount: 8.83M | Year: 2015
Diabetes mellitus is a chronic disease characterised by high blood glucose due to inadequate insulin production and/or insulin resistance which affects 382 million people worldwide. Pancreatic islet transplantation is an extremely promising cure for insulin-sensitive diabetes mellitus (ISDM), but side effects of lifelong systemic immunosuppressive therapy, short supply of donor islets and their poor survival and efficacy in the portal vein limit the application of the current clinical procedure to the most at-risk brittle Type I diabetes (T1D) sufferers. The DRIVE consortium will develop a novel suite of bio-interactive hydrogels (-Gel) and on-demand drug release systems to deliver islets in a protective macrocapsule (-Shell) to the peritoneum with targeted deposition using a specialised injection catheter (-Cath). Pancreatic islets will be microencapsulated in -Gels; biofunctionalised injectable hydrogels containing immunosuppressive agents and polymeric microparticles with tuneable degradation profiles for localised delivery of efficacy cues. These -Gels will be housed in a porous retrievable macrocapsule, -Shell, for added retention, engraftment, oxygenation, vascularisation and immunoprotection of the islets. A minimally invasive laparoscopic procedure (O-Fold) will be used to create an omental fold and at the same time deliver -Shell. An extended residence time in -Gel will enhance long-term clinical efficacy of the islets and result in improved glycemic control. The novel -Gels will also be developed as human three-dimensional in-vitro models of in-vivo behaviour. Islet harvesting and preservation technologies will be developed to facilitate their optimised yield, safe handling and transport, and ease of storage. DRIVE will also enable the future treatment of a broader range of T1 and insulin-sensitive T2 diabetics by working with induced pluripotent stem cell experts to ensure the compatibility of our system with future stem cell sources of -cells.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: NMBP-10-2016 | Award Amount: 5.85M | Year: 2017
Lysosomal storage disorders (LSD) diseases are a group of rare diseases that currently lack a definitive cure. LSD incidence is about 1:5,000 - 1:10,000, representing a serious global health problem. In the case of Fabry LSD Disease (FD), the deficiency in -Galactosidase A (GLA) enzyme activity results in the cellular accumulation of neutral glycosphingolipids, leading to widespread vasculopathy with particular detriment to the kidneys, heart and nervous system. The current treatment for FD is the Enzyme Replacement Therapy (ERT), in which free GLA recombinant protein is administered intravenously to patients. ERT exhibits several drawbacks mainly related to the instability, high immunogenicity and low efficacy of the exogenously administered GLA to cross biological barriers, such as cell membranes and BBB.The aim of Samrt-4-Fabry project is to achieve excellent quality control over the assembly of the different molecular components of a new liposomal nanoformulation of GLA, nano-GLA, for the treatment of Fabry disease. Nanoformulated GLA has already shown to have better PK/PD profile than free GLA and higher efficacy in vivo. Smart-4-Fabry project will advance nano-GLA from an experimental PoC (TRL3) to preclinical regulatory phase (TRL5-6). A one-step method based on the use of green cCO2, will be used for the manufacturing of this novel nanoformulation under GMPs. The final GLA nanoformulation will have tailored transport of GLA through cell membranes and BBB. Fulfillment of Smart-4-Fabry will impact on a major health problem, the existence of new therapies for rare diseases, which constitutes a priority societal challenge as shown in the H2020 Work Programmes. Another important impact is related to its contribution to support the European Strategy for KETs, which aims to reverse the decline in manufacturing as this will stimulate growth and jobs. Smart-4-Fabry is strongly focusing on three KETs: nanotechnology, industrial biotechnology and advanced materials.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: ICT-09-2014 | Award Amount: 3.57M | Year: 2015
The RePhrase project directly meets the challenge of ICT-09-2014, by studying the critically important issue of improving software development practice for parallel data-intensive applications. Data-intensive applications are among the most important and commonly encountered kinds of industrial application, and are increasingly important with the emergence of big data problems. Emerging heterogeneous parallel architectures form ideal platforms to exploit the massive-scale inherent parallelism that is usually implicit in such applications, but which is often difficult to extract in practice. Solving this problem will bring major economic benefits to the software industry. To address this challenge, RePhrase brings together a team of leading industrial and academic researchers, software engineers, systems developers, parallelism experts and domain experts from large companies, SMEs and leading universities. It aims to develop a novel software engineering methodology for developing complex, large-scale parallel data-intensive applications, supported by a very high-level programming model. We will exploit advanced pattern-based programming, refactoring, testing, debugging, verification and adaptive-scheduling technologies to build an interoperable tool-chain supporting our methodology, based on but significantly extending existing industrial and research tools. These tools will significantly ease, and even automate, all phases of typical software development, from design and implementation to long-term maintenance and software evolution. The generality of our approach will be ensured by targeting C\\ and the most popular low-level parallel programming models, such as the C\\11/14/17 standards, pthreads, OpenMP, Intel TBB, OpenCL and CUDA. We will demonstrate our approach on a range of large-scale data-intensive applications, taken from different domains, including bio-medical image processing, data analysis, machine learning, computer vision and railway diagnosis.